With Bioventus reporting a solid 15% revenue increase and a significant turnaround in cash flow, I believe the stock is positioned for continued growth. Given the recent price rebound of over 120%, I think it’s looking good for a swing trade as it moves towards stronger recovery.

Considering the significant growth forecast for the osteoarthritis therapeutics market and Bioventus's promising position within this sector, I believe purchasing BVS aligns well with the anticipated market expansion, providing a strong potential for appreciation in value as the company continues to innovate and capture market share.